Latest stories on AGMB
AgomAb Therapeutics: Building A New Treatment Layer In Fibrosis
Seeking Alpha63 · neutralproduct/pr
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
GlobeNewswire67 · bullishproduct/pr
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
Business Insider67 · bullishproduct/pr
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
StockTitan55 · neutralgeneral
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Business Insider50 · neutralgeneral
Agomab to Participate in Upcoming Investor Conferences
Business Insider55 · neutralgeneral
Agomab to Participate in Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Agomab initiated with an Overweight at Piper Sandler
The Fly61 · neutralanalyst
Piper Sandler initiates Agomab stock with Overweight rating
Investing.com Analyst Ratings61 · neutralanalyst
Agomab initiated with an Overweight at Cantor Fitzgerald
The Fly61 · neutralanalyst
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
StockTitan50 · neutralgeneral
AgomAb Therapeutics NV reports 1H results
Seeking Alpha48 · neutralearnings
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
StockTitan56 · neutralgeneral
B.Riley initiates Agomab Therapeutics stock with buy rating
Investing.com Analyst Ratings61 · neutralanalyst
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
Yahoo Finance56 · neutralanalyst
Agomab, FDA Agree on Phase 2b Trial for Crohn's Disease Treatment
Morningstar63 · neutralproduct/pr
Agomab Details Nov Era Phase 2b Trial Design For Ontunisertib In Fibrostenosing Crohns Disease
TipRanks56 · neutralproduct/pr
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease | AGMB Stock News
StockTitan63 · neutralproduct/pr
AgomAb Therapeutics: High Risk, High Reward Stock
Seeking Alpha65 · bullishanalyst
Agomab Announces Results of Annual General Meeting | AGMB Stock News
StockTitan50 · neutralgeneral